Dual fluorescence in situ hybridization in detection of HER-2 oncogene amplification in primary hepatocellular carcinoma

Hepatobiliary and Pancreatic Diseases International

Volumn 3, Issue 1, 2004, Pages 62-68

  Huang, Tie Jun ^a   Huang, Bi Jun ^b   Liang, Qi Wan ^b   Huang, Chu Wen ^b   Fang, Yan ^b  

^a The 2nd Shenzhen People s Hospital   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Amplification; Dual fluorescence in situ hybridization; Hepatocellular carcinoma, primary; HER 2 oncogene

Indexed keywords

ALPHA FETOPROTEIN; ONCOPROTEIN;

ADULT; ANEUPLOIDY; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 17; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE FREQUENCY; GENETIC ANALYSIS; HEPATITIS B; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MALE; ONCOGENE NEU; PROGNOSIS; SURVIVAL TIME; TUMOR SUPPRESSOR GENE; TUMOR VOLUME;

ADULT; BIOPSY, NEEDLE; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; CULTURE TECHNIQUES; FEMALE; GENE AMPLIFICATION; GENES, ERBB-2; HEPATECTOMY; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LIVER NEOPLASMS; MALE; MIDDLE AGED; ONCOGENES; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

EID: 1342265923     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Okamoto H, Yasui K, Zhao C, Arii S, Inazawa J. PTK2 and EIF3S3 genes may be amplification targets at 8q23-q24 and are associated with large hepatocellular carcinomas. Hepatology 2003;38:1242-1249.
2. Arai H, Ueno T, Tangoku A, Yoshino S, Abe T, Kawauchi S, et al. Detection of amplified oncogenes by genome DNA microarrays in human primary esophageal squamous cell carcinoma: comparison with conventional comparative genornic hybridization analysis. Cancer Genet Cytogenet 2003;146:16-21.
3. Matsuo K, Satoh S, Okabe H, Nomura A, Maeda T, Yamaoka Y, et al. SIAH1 inactivation correlates with tumor progression in hepatocellular carcinomas. Genes Chromosomes Cancer 2003;36:283-291.
4. Thompson PM, Maris JM, Hogarty MD, Seeger RC, Reynolds CP, Brodeur GM, et al. Homozygous deletion of CD-KN2A (p16-INK4a/p14ARF) but not within 1p36 or at other tumor suppressor loci in neuroblastoma. Cancer Res 2001;61: 679-686.
5. Squire JA, Pei J, Marrano P, Beheshti B, Bayani J, Lim G, et al. High-resolution mapping of amplifications and deletions in pediatric osteosarcoma by use of CGH analysis of cDNA microarrays. Genes Chromosomes Cancer 2003;38:215-225.
6. Allgayer H, Babic R, Gruetzner KU, Tarabichi A, Schildberg FW, Heiss MM. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol 2000;18:2201-2209.
7. Gusterson BA, Gelbert RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, et al. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 1992;10: 1049-1056.
8. Afify AM, Werness BA, Mark HF. HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma. Exp Mol Pathol 1999;66:163-169.
9. Tang Z, Qin L, Wang G, Zhou G, Liao Y, Weng Y, et al. Alterations of oncogenes, tumor suppressor genes and growth factors in hepatocellular carcinoma: with relation to tumor size and invasiveness. Chin Med J (Engl) 1998;111:313-318.
10. Wong N, Lai P, Lee SW, Fan S, Pang E, Liew CT, et al. Assessment of genetic changes in hepatocellular carcinoma by comparative genomic hybridization analysis: relationship to disease stage, tumor size, and cirrhosis. Am J Pathol 1999;154: 37-43.
11. Shi BM, Wang XY, Mu QL, Wu TH, Yang Z, Zhang L, et al. Expressions of vascular endothelial growth factor in cirrhotic tissues and their relations to proto-oncogene c-fos, c-myc. Hepatobiliary Pancreat Dis Int 2002;1:388-391.
12. Huang YX, Fang Y, Guo Y. Study of cyclin D1 gene amplification in nasopharyngeal carcinoma using interphase FISH. Chin J Cancer 2000;19:20-22.
13. Persons DL, Bui MM, Lowery MC, Mark HF, Yung JF, Birkmeier JM, et al. Fluorescence in situ hybridization (FISH) for detection of HER-2/neu amplification in breast cancer: a muticenter portability study. Ann Clin Lab Sci 2000;30:41-48.
14. Bozzetti C, Personeni N, Nizzoli R, Guazzi A, Flora M, Bassano C, et al. HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma. Cancer 2003;99:310-315.
15. Nathanson DR, Culliford AT, Shia J, Chen B, D'Alessio M, Zeng ZS, et al. HER2/neu expression and gene amplification in colon cancer. Int J Cancer 2003;105:796-802.
16. Masood S, Bui MM. Prognostic and predictive value of HER2/neu oncogene in breast cancer. Microsc Res Tech 2002;59:102-108.
17. Ukita Y, Kato M, Terada T. Gene amplification and mRNA and protein overexpression of c-erbB-2 (HER-2/neu in human intrahepatic cholangiocarcinoma as detected by fluorescence in situ hybridization, in situ hybridization, and immunohistochemistry. J Hepatol 2002;36:780-785.
18. Aishima SI, Taguchi KI, Sugimachi K, Shimada M, Sugimachi K, Tsuneyoshi M. c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma. Histopathology 2002;40:269-278.
19. Nakamura H, Saji H, Ogata A, Hosaka M, Hagiwara M, Kawasaki N, et al. Correlation between encoded protein overexpression and copy number of the HER2 gene with survival in non-small cell lung cancer. Int J Cancer 2003;103:61-66.
20. Zhou H, Randall RL, Brothman AR, Maxwell T, Coffin CM, Goldsby RE. Her-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification. J Pediatr Hematol Oncol 2003;25:27-32.
21. Dowsett M, Bartlett J, Ellis IO, Salter J, Hills M, Mallon E, et al. Correlation between immunohistochemistry (Hercep-Test) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol 2003;199: 411-417.
22. Molina R, Jo J, Filella X, Bruix J, Castells A, Hague M, et al. Serum levels of HER-2/neu in patients with malignant and non-malignant diseases. Tumour Biol 1997;18:188-196.
23. Heinze T, Jonas S, Karsten A, Neuhaus P. Determination of the oncogenes p53 and c-erbB-2 in the tumour cytosols of advanced hepatocellular carcinoma (HCC) and correlation to survival time. Anticancer Res 1999;19:2501-2503.
24. Cianciulli AM, Guadagni F, Marzano R, Benevolo M, Merola R, Giannarelli D, et al. HER-2/neu oncogene amplification and chromosome 17 aneusomy in endometrial carcinoma: correlation with oncoprotein expression and conventional pathological parameters. J Exp Clin Cancer Res 2003;22:265-271.
25. Watters AD, Going JJ, Cooke TG, Bartlett JM. Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma. Breast Cancer Res Treat 2003;77:109-114.
26. Liu Y, Wu MC, Qian GX, Zhang BH. Nested RT-PCR in detection of blood AFPmRNA in animal model of human hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2003;2: 414-417.
27. Zekri AR, Bahnassy AA, Shaarawy SM, Mansour CA, Maduar MA, Khaled HM, et al. Hepatitis C virus genotyping in relation to neu-oncoprotein overexpression and the development of hepatocellular carcinoma. J Med Microbiol 2000;49:89-95.
28. Press MF, Hung G, Godolphin W, Slamon DJ. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994;54:2771-2777.
29. Sauer T, Wiedswang G, Boudjema G, Christensen H, Karesen R. Assessment of HER-2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be the method of choice? APMIS 2003;111:444-450.
30. O'Grady A, Flahavan CM, Kay EW, Barrett HL, Leader MB. HER-2 analysis in tissue microarrays of archival human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. Appl Immunohistochem Mol Morphol 2003;11:177-182.
31. Hoang MP, Sahin AA, Ordonez NG, Sneige N. HER-2/neu gene amplification compared vAth HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. Am J Clin Pathol 2000;113:852-859.
32. Shen BY, Li HW, Regimbeau JM, Belghiti J. Recurrence after resection of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2002;1:401-405.
33. Zhou XD. Recurrence and metastasis of hepatocellular carcinoma: progress and prospects. Hepatobiliary Pancreat Dis Int 2002;1:35-41.
34. Blum HE. Molecular therapy and prevention of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2003;2:11-22.